Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $25

Ultragenyx Pharmaceutical, Inc. +1.18% Pre

Ultragenyx Pharmaceutical, Inc.

RARE

24.81

24.66

+1.18%

-0.60% Pre
Goldman Sachs analyst Salveen Richter downgrades Ultragenyx Pharmaceutical (NASDAQ: RARE) from Buy to Neutral and lowers the price target from $61 to $25.